An Open-label, Multi-center, Phase 1/2 Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Participants With Difficult-to-treat Rheumatoid Arthritis and Severe, Refractory Sjogren's Disease With Organ Involvement
Latest Information Update: 18 Aug 2025
At a glance
- Drugs Rapcabtagene autoleucel (Primary)
- Indications Rheumatoid arthritis; Sjogren's syndrome
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 15 Jul 2025 Planned End Date changed from 14 Jul 2028 to 15 Sep 2028.
- 15 Jul 2025 Planned primary completion date changed from 2 Jun 2028 to 15 Sep 2028.
- 10 Jul 2025 New trial record